Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group.
about
Commercial taxane formulations induce stomatocytosis and increase blood viscosityClinical Toxicities of Histone Deacetylase Inhibitors.Treatment options in androgen-independent prostate cancer.Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.Taxanes in hormone-refractory prostate cancer.Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life.Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder.Pharmacological treatments for prostate cancer.Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer.New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cellsAcute Myocardial Infarction in Patient With Triple Negative Breast Cancer After Paclitaxel Infusion: A Case Report.Endophytic fungi: novel sources of anticancer lead molecules.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Taxanes: a new class of antitumor agents.Paclitaxel (taxol).Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.Fatal myocardial infarction potentially induced by paclitaxel.Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer.Estramustine plus a taxane for advanced prostate cancer: the new standard therapy?Doxazosin: a new cytotoxic agent for prostate cancer?
P2860
Q28363722-E3C50B9E-B090-4451-AB1A-28ED19A5487CQ31135325-78194767-273B-470A-AB35-5164D294EE69Q33539954-54200977-C1DA-426A-98B7-5D9D56815577Q33597393-7A1438BC-67FF-464F-A14E-77DA5C468138Q33845088-AFB4BA95-D014-469C-9CD4-F96A1A63D770Q33939310-5C9A0238-921E-4634-822A-62888E904A89Q34057806-815DB0B1-19F3-4658-ACED-54C1919E07CCQ35011889-A19C56AA-0F48-410F-A67B-F6494F80D638Q35127916-6EDBD3D1-A09A-4CE6-A674-0CA1BAF8938DQ36066144-B39BCA5F-B53E-4012-A267-38BA0468AA30Q36291736-E020F793-4C13-4B3A-AD66-AE4216950531Q37711306-CA4DB357-C995-4A9C-80AF-7CD8FAA33CC7Q38012633-D6FD50B6-D66B-4712-8BA7-CC3C6A5011A8Q38099046-4D54A6D9-7779-43B3-8779-DEB3CD1E3DC9Q40456125-BF1C7EFC-1A7B-4BDF-832B-9E65CF301103Q40622290-B47ED526-FFB4-4E8E-9100-3C7D5088BF57Q40754620-AB620469-DCD8-48BE-8FE2-89FF410304A6Q42552793-75573A90-019B-496A-8A0B-CF2C833276ACQ44115416-613EC553-2FD0-4A00-87BA-1C5B43A9D49CQ44115448-9F13FB45-49EC-43CD-816B-04B0F7EAE819Q50512920-F0543775-B59C-4FB7-B319-EFCEA19688FE
P2860
Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Taxol in advanced, hormone-ref ...... rn Cooperative Oncology Group.
@en
type
label
Taxol in advanced, hormone-ref ...... rn Cooperative Oncology Group.
@en
prefLabel
Taxol in advanced, hormone-ref ...... rn Cooperative Oncology Group.
@en
P2093
P1433
P1476
Taxol in advanced, hormone-ref ...... rn Cooperative Oncology Group.
@en
P2093
P304
P356
10.1002/1097-0142(19931015)72:8<2457::AID-CNCR2820720825>3.0.CO;2-Z
P407
P577
1993-10-01T00:00:00Z